Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific director Christophe Pierre Weber reported equity-based compensation grants. On May 7, 2026, he received 1,140 shares of restricted stock in lieu of 80% of his yearly cash retainer, reflecting a value of approximately $100,000 based on the grant-date closing price.
He also received an annual equity award of 1,767 restricted shares, tied to a program value of $215,000, with $64,500 representing 30% of that award. In addition, he was granted 2,660 Deferred Stock Units, tied to $150,500 (70% of the annual equity award), which convert into common shares after his service on the board ends. All equity awards vest in full at the next annual meeting of stockholders.
Smith Cathy R reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cathy R. Smith received equity compensation in the form of deferred stock units. On 2026-05-07, she was granted 2,209 deferred stock units tied to common stock as an annual equity award valued at $215,000, plus 3,800 additional deferred stock units granted in lieu of $125,000 of yearly cash compensation.
Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock. Both awards vest in full at the next annual meeting of stockholders, with shares delivered only after she leaves the Board under the Non-Employee Director Deferred Compensation Plan. Following these grants, reported deferred stock unit balances in the respective plans were 6,888 and 4,679 units.
Pegus Cheryl reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cheryl Pegus received two compensation grants of deferred stock units, not open-market purchases or sales. On May 7, 2026, she was awarded 3,800 deferred stock units representing an annual equity award valued at $215,000, based on the closing share price that day. She also received 1,281 deferred stock units granted in lieu of 50% of her yearly cash and committee chair retainers, reflecting a value of $72,500 divided by the same closing price. Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock, vesting in full at the next annual stockholders’ meeting, with shares delivered after she leaves Board service under the Non-Employee Director Deferred Compensation Plan. Following these awards, she directly holds 10,998 deferred stock units.
Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Susan E. Morano reported two equity compensation grants of common stock. She received 1,281 shares as an annual equity award of restricted stock and 3,800 shares of restricted stock granted in lieu of 50% of her yearly cash compensation. Both grants vest in full at the next annual meeting of stockholders.
The annual equity award reflects a value of $215,000 based on the closing share price on the grant date. The stock granted in place of cash has an approximate value of $72,500, tied to the non-employee director cash retainer and committee chair retainer. These are compensation-related awards, not open‑market share purchases or sales.
Mega Jessica L reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Jessica L. Mega received an annual equity award of 3,800 shares of Common Stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. The footnote explains the grant reflects a value of $215,000 divided by the closing price of the common stock on the grant date. Following this compensation-related award, she directly holds 12,035 shares of Boston Scientific common stock.
Boston Scientific director Edward J. Ludwig received an annual equity award in the form of restricted stock. On the grant date, he acquired 3,800 shares of common stock at no cash cost as a grant or award. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date. These restricted shares vest in full at the next annual meeting of stockholders. Following this grant, Ludwig directly holds 21,779 shares of Boston Scientific common stock.
Habiger David C reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director David C. Habiger received an annual equity award of 3,800 shares of common stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. According to the filing, the grant reflects a value of $215,000, based on the closing price of the common stock on the grant date. After this grant, Habiger directly holds 9,428 shares of Boston Scientific common stock.
Boston Scientific Corp: FMR LLC reports beneficial ownership of 75,835,683.30 shares of Common Stock, equal to 5.1% of the class. The filing (Amendment No. 5 to Schedule 13G/A) lists sole dispositive power for 75,835,683.30 shares and sole voting power for 65,765,394.36 shares. Signature pages show authority via power of attorney and dates associated with the amendment and signatures.
Boston Scientific Corporation held its 2026 Annual Meeting of Stockholders in a virtual-only format, where stockholders approved key changes to the company’s charter and governance framework. The company’s Fourth Restated Certificate of Incorporation became effective after stockholders voted to remove supermajority voting provisions and to add exculpation protections for certain officers as permitted by Delaware law.
All 10 director nominees were elected for one-year terms, stockholders approved the advisory vote on compensation for named executive officers, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year. Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase shares reserved, while two stockholder proposals related to giving shareholders the ability to call special meetings did not receive sufficient support.
Boston Scientific EVP Padraig Andrew O'Connor reported routine equity compensation activity involving restricted stock units. On May 2, 2026, he exercised awards covering 1,802 restricted stock units, receiving the same number of shares of Boston Scientific common stock.
To satisfy tax obligations related to this vesting, 872 common shares were disposed of at $56.50 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, O'Connor directly holds 7,024 shares of common stock.